Compare Repligen Corporation Common Stock (RGEN) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Consumer Discretionary Select Sector SPDR Fund trades at $111.34 (market cap $21.98B). The key difference: Consumer Discretionary Select Sector SPDR Fund is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Consumer Discretionary Select Sector SPDR Fund for 115 Days on average.
| RGEN | XLY | |
|---|---|---|
Market Cap | $11.14B | $21.98B |
Volume | 1,259,263 | 5,684,050 |
Sector | Health | — |
52-Week High | $194.57 | $124.52 |
52-Week Low | $102.87 | $105.64 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
XLY trades at $112.36 with minimal daily movement (+0.07%), showing technical indecision with a bullish overall signal but bearish moving averages. The ETF has underperformed the broader market in 2026, declining over 7% while consumer staples gained 6.6%. Analyst consensus remains unanimously bullish with a 100% buy rating, though recent news highlights persistent underperformance concerns and consumer spending shifts toward value.
The outlook remains mixed with technical indicators suggesting potential resistance near $113 while fundamental exposure to consumer discretionary spending faces inflation pressures. Key risks include continued market underperformance and consumer sensitivity to economic conditions, though potential catalysts exist from holiday retail growth projections and cyclical sector opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
